UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 60

Sortiert nach

Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer

Cell death and differentiation, 2019-10, Vol.26 (10), p.2100-2114

2019

Volltextzugriff (PDF)

Photon management by scratch‐resistant antireflection coating for the efficiency enhancement of silicon solar cell

International journal of energy research, 2022-09, Vol.46 (11), p.15485-15498

2022

Volltextzugriff (PDF)

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

PloS one, 2012-01, Vol.7 (1), p.e30815

2012

Volltextzugriff (PDF)

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Molecular cancer therapeutics, 2015-01, Vol.14 (1), p.101-110

2015

Volltextzugriff (PDF)

Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer

Oncotarget, 2013-09, Vol.4 (12), p.2225-2236

2013

Volltextzugriff (PDF)

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

BMC cancer, 2016-08, Vol.16 (1), p.617-617, Article 617

2016

Volltextzugriff (PDF)

Race-specific coregulatory and transcriptomic profiles associated with DNA methylation and androgen receptor in prostate cancer

Genome medicine, 2024-04, Vol.16 (1), p.52-17, Article 52

2024

Volltextzugriff (PDF)

Serum Androgen Metabolites Correlate with Clinical Variables in African and European American Men with Localized, Therapy Naïve Prostate Cancer

Metabolites, 2023-02, Vol.13 (2), p.284

2023

Volltextzugriff (PDF)

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer

PloS one, 2014-07, Vol.9 (7), p.e103680-e103680

2014

Volltextzugriff (PDF)

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models

Cancer immunology research, 2015-02, Vol.3 (2), p.136-148

2015

Volltextzugriff (PDF)

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression

PloS one, 2011-11, Vol.6 (11), p.e27178

2011

Volltextzugriff (PDF)

Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma

The cancer journal (Sudbury, Mass.), 2013-07, Vol.19 (4), p.333

2013

Volltextzugriff (PDF)

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage

Oncogene, 2016-03, Vol.35 (12), p.1541-1553

2016

Volltextzugriff (PDF)

Abstract A22: STAG2, a novel genetic regulator of bladder cancer

Clinical cancer research, 2020-08, Vol.26 (15_Supplement), p.A22-A22

2020

Volltextzugriff (PDF)

Abstract PO-134: Intracellular calcium regulates androgen receptor expression and basal-luminal features in prostate cancer from African American men

Cancer epidemiology, biomarkers & prevention, 2020-12, Vol.29 (12_Supplement), p.PO-134-PO-134

2020

Volltextzugriff (PDF)

Abstract B087: Role of GATA-4-Androgen-AR axis in prostate cancer from African American men

Cancer epidemiology, biomarkers & prevention, 2020-06, Vol.29 (6_Supplement_2), p.B087-B087

2020

Volltextzugriff (PDF)

Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma

Molecular cancer therapeutics, 2020-01, Vol.19 (1), p.147-156

2020

Volltextzugriff (PDF)

TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)

Cell cycle (Georgetown, Tex.), 2019-09, Vol.18 (17), p.2055-2066

2019

Volltextzugriff (PDF)

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Molecular cancer therapeutics, 2015-02, Vol.14 (2), p.513-522

2015

Volltextzugriff (PDF)

Histone modifications: implications in renal cell carcinoma

Epigenomics, 2013-08, Vol.5 (4), p.453-462

2013

Volltextzugriff (PDF)

Abstract A003: Epigenetic alterations as potential biologic determinants of racial health disparities

Cancer research (Chicago, Ill.), 2018-08, Vol.78 (16_Supplement), p.A003-A003

2018

Volltextzugriff (PDF)

Development of a castrate resistant transplant tumor model of prostate cancer

The Prostate, 2012-05, Vol.72 (6), p.587-591

2012

Volltextzugriff (PDF)

Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer

Cell death & disease, 2017-12, Vol.8 (12), p.3217-13, Article 3217

2017

Volltextzugriff (PDF)

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

Oncotarget, 2015-02, Vol.6 (5), p.3136-3146

2015

Volltextzugriff (PDF)

Abstract B72: DNA methylation and genetic alterations contribute to aggressive prostate cancer in African American men

Cancer epidemiology, biomarkers & prevention, 2018-07, Vol.27 (7_Supplement), p.B72-B72

2018

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(56)

Publikationsform

Sprache

Englisch
(60)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer

Photon management by scratch‐resistant antireflection coating for the efficiency enhancement of silicon solar cell

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

Race-specific coregulatory and transcriptomic profiles associated with DNA methylation and androgen receptor in prostate cancer

Serum Androgen Metabolites Correlate with Clinical Variables in African and European American Men with Localized, Therapy Naïve Prostate Cancer

Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression

Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage

Abstract A22: STAG2, a novel genetic regulator of bladder cancer

Abstract PO-134: Intracellular calcium regulates androgen receptor expression and basal-luminal features in prostate cancer from African American men

Abstract B087: Role of GATA-4-Androgen-AR axis in prostate cancer from African American men

Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma

TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Histone modifications: implications in renal cell carcinoma

Abstract A003: Epigenetic alterations as potential biologic determinants of racial health disparities

Development of a castrate resistant transplant tumor model of prostate cancer

Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

Abstract B72: DNA methylation and genetic alterations contribute to aggressive prostate cancer in African American men

Suchergebnisse filtern